Show simple item record

dc.contributor.authorWelsch, Julia
dc.contributor.authorKup, Philipp Günther
dc.contributor.authorNieder, Carsten
dc.contributor.authorKhosrawipour, Veria
dc.contributor.authorBühler, Helmut
dc.contributor.authorAdamietz, Irenäus A.
dc.contributor.authorFakhrian, Khashayar
dc.date.accessioned2017-03-10T17:01:55Z
dc.date.available2017-03-10T17:01:55Z
dc.date.issued2016-01-01
dc.description.abstract<b>Purpose:</b> The aim of this study was to assess the 6-months dysphagia-free survival, improvement in swallowing function, complication rate, and overall survival in patients with incurable esophageal cancer treated with palliative radiotherapy. <b>Methods:</b> We retrospectively reviewed data from 139 patients (median age 72 years) with advanced/recurrent incurable esophageal cancer, who were referred to 3 German radiation oncology centers for palliative radiotherapy between 1994 and 2014. Radiotherapy consisted of external beam radiotherapy (EBRT) with 30 - 40.5 Gy/2.5 - 3 Gy per fraction, brachytherapy alone (BT) with 15 - 25 Gy/5 - 7Gy per fraction/weekly and EBRT + BT (30 - 40.5 Gy plus 10 - 14 Gy with BT) in 65, 46, and 28 patients, respectively. Dysphagia-free survival (Dy-PFS) was defined as the time to worsening of dysphagia for at least one point, a new loco-regional failure or death of any cause. <b>Results:</b> Median follow-up time was 6 months (range 1-6 months). Subjective symptom relief was achieved in 72 % of patients with median response duration of 5 months. The 1-year survival rate was 30%. The 6-months Dy-PFS time for the whole group was 73 ± 4%. The 6-months Dy-PFS was 90 ± 4% after EBRT, 92 ± 5% after EBRT + BT and 37 ± 7% after BT, respectively (p<0.001). Five patients lived for more than 2 years, all of them were treated with EBRT ± BT. Ulceration, fistula and stricture developed in 3, 6 and 7 patients, respectively. <b>Conclusions:</b> Radiotherapy leads to symptom improvement in the majority of patients with advanced incurable esophageal cancer. The present results favor EBRT ± BT over BT alone. Due to the retrospective nature of this study, imbalances in baseline characteristics might have contributed to this finding, and further trials appear necessary.en_US
dc.descriptionSource:<a href=https://www.ub.uit.no/munin/bitstream/item/11977/article.pdf?sequence=2>https://doi:10.7150/jca.13655</a>en_US
dc.identifier.citationWelsch, Kup PG, Nieder C, Khosrawipour, Bühler, Adamietz IA, Fakhrian K. Survival and symptom relief after palliative radiotherapy for esophageal cancer. Journal of Cancer. 2016;7(2):125-130en_US
dc.identifier.cristinIDFRIDAID 1371268
dc.identifier.doi10.7150/jca.13655
dc.identifier.issn1837-9664
dc.identifier.urihttps://hdl.handle.net/10037/10559
dc.language.isoengen_US
dc.publisherIvyspring. Journal of Cancer 2016; 7(2):125-130.en_US
dc.relation.journalJournal of Cancer
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectEsophageal canceren_US
dc.subjectPalliationen_US
dc.subjectExternal beam radiation therapyen_US
dc.subjectBrachytherapyen_US
dc.subjectDysphagia-free survivalen_US
dc.subjectComplicationsen_US
dc.titleSurvival and symptom relief after palliative radiotherapy for esophageal canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record